GlassScriptPhysician profile
Jesse M Gronback
NPI 1487971412
$3,000.01
in general payments reported to CMS, 2019-2025
17 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $26.02 · 2023: $1,802 · 2024: $1,050 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,973.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.55 | 2023-2024 | |
| Axsome Therapeutics, INC. | $368.13 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $308.43 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $269.55 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $244.50 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $141.62 | 2023-2024 | Trintellix |
| Noven Therapeutics, LLC | $140.66 | 2023-2024 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $89.83 | 2023-2024 | Jornay Pm |
| Neos Therapeutics, LP | $86.71 | 2023-2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $75.16 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $71.20 | 2023-2024 | Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $69.73 | 2023 | Qelbree |
| Tris Pharma INC | $40.97 | 2023-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $37.91 | 2024 | Fanapt |
| Neurocrine Biosciences, INC. | $32.26 | 2023 | Ingrezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $19.03 | 2023 | Aristada, Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Gronback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.